TARGETED THERAPIES Afatinib-new therapy option for EGFR-mutant lung cancer

被引：82

作者：

Yu, Helena A. ^{[1
]}

Pao, William ^{[2
]}

机构：

[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv,Div Solid Tumor Oncol, New York, NY 10065 USA

[2] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN 37212 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2013年 / 10卷 / 10期

关键词：

1ST-LINE TREATMENT; OPEN-LABEL; ERLOTINIB; CHEMOTHERAPY; MULTICENTER; PHASE-3; TRIAL;

D O I：

10.1038/nrclinonc.2013.154

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of patients.

引用

页码：551 / 552

页数：2

共 50 条

[21] Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial
Yonesaka, Kimio
Hayashi, Hidetoshi
Nakamura, Atsushi
Sato, Yuki
Azuma, Koichi
Sakata, Shinya
Tachihara, Motoko
Ikeda, Satoshi
Yokoyama, Toshihide
Ito, Kentaro
Yano, Yukihiro
Matsumoto, Hirotaka
Daga, Haruko
Hata, Akito
Sakai, Kazuko
Chiba, Yasutaka
Nishio, Kazuto
Yamamoto, Nobuyuki
Nakagawa, Kazuhiko
CLINICAL LUNG CANCER, 2023, 24 (06) : 519 - +
[22] Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience
Kudo, Kenichiro
Hotta, Katsuyuki
Bessho, Akihiro
Nogami, Naoyuki
Kozuki, Toshiyuki
Kuyama, Shoichi
Inoue, Koji
Harita, Shingo
Okada, Toshiaki
Gemba, Kenichi
Fujii, Masanori
Takigawa, Nagio
Oda, Naohiro
Tanimoto, Mitsune
Kiura, Katsuyuki
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) : 1005 - 1009
[23] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
Otsuka, Kyoko
Hata, Akito
Takeshita, Jumpei
Okuda, Chiyuki
Kaji, Reiko
Masago, Katsuhiro
Fujita, Shiro
Katakami, Nobuyuki
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
[24] Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer Reply
Wu, Yi-Long
Zhong, Wen-Zhao
LANCET ONCOLOGY, 2018, 19 (03) : E127 - E127
[25] Lung cancer's real adjuvant EGFR targeted therapy questions
Ng, Terry L.
Camidge, D. Ross
LANCET ONCOLOGY, 2018, 19 (01) : 15 - 17
[26] Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
Takahashi, Akiko
Seike, Masahiro
Chiba, Mika
Takahashi, Satoshi
Nakamichi, Shinji
Matsumoto, Masaru
Takeuchi, Susumu
Minegishi, Yuji
Noro, Rintaro
Kunugi, Shinobu
Kubota, Kaoru
Gemma, Akihiko
SCIENTIFIC REPORTS, 2018, 8
[27] Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer
Choi, Mihong
Keam, Bhumsuk
Ock, Chan-Young
Kim, Miso
Kim, Tae Min
Kim, Dong-Wan
Heo, Dae Seog
CLINICAL LUNG CANCER, 2019, 20 (04) : E442 - E451
[28] EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib
Hara, Reina
Kanazu, Masaki
Iwai, Ami
Kuge, Tomoki
Ishijima, Mikako
Uenami, Takeshi
Akazawa, Yuki
Yano, Yukihiro
Yamaguchi, Toshihiko
Mori, Masahide
THORACIC CANCER, 2021, 12 (09) : 1441 - 1444
[29] Outcomes of salvage lung resections in advanced EGFR-mutant lung adenocarcinomas under EGFR TKIs
Chen, Ying-Yuan
Yen, Yi-Ting
Lai, Wu-Wei
Huang, Wei-Li
Chang, Chao-Chun
Tseng, Yau-Lin
THORACIC CANCER, 2021, 12 (20) : 2655 - 2665
[30] ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?
Piotrowska, Zofia
Gainor, Justin F.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) : 2241 - +

← 1 2 3 4 5 →